Citius Pharmaceuticals Inc CTXR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CTXR is a good fit for your portfolio.
News
-
Citius Pharmaceuticals Announces $15 Million Registered Direct Offering
-
Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma
-
Citius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor Conference
-
Thinking about buying stock in Velo3D, Nova Lifestyle, indie Semiconductor, Citius Pharmaceuticals, or Transcode Therapeutics?
-
Citius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma
-
Citius Pharmaceuticals, Inc. Secures $2.4 million through New Jersey Economic Development Program
-
Citius Pharmaceuticals Announces Filing of Form S-3 Shelf Registration Statement to Replace Expiring Prior Shelf Registration
-
Citius Pharmaceuticals to Participate in Upcoming BIO CEO and Sidoti Investor Conferences
Trading Information
- Previous Close Price
- $0.73
- Day Range
- $0.64–0.69
- 52-Week Range
- $0.60–1.56
- Bid/Ask
- $0.66 / $0.67
- Market Cap
- $105.77 Mil
- Volume/Avg
- 2.8 Mil / 889,737
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. It is currently advancing four proprietary product candidates: LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma . Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory distress syndrome.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 22
- Website
- https://www.citiuspharma.com
Comparables
Valuation
|
Metric
|
CTXR
|
CRNX
|
KROS
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.37 | 5.33 | 5.55 |
Price/Sales | — | 609.51 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
CTXR
|
CRNX
|
KROS
|
|---|---|---|---|
Quick Ratio | 3.65 | 12.92 | 13.63 |
Current Ratio | 5.06 | 13.07 | 14.25 |
Interest Coverage | — | — | — |
Quick Ratio
CTXR
CRNX
KROS
Profitability
|
Metric
|
CTXR
|
CRNX
|
KROS
|
|---|---|---|---|
Return on Assets (Normalized) | −29.85% | −38.81% | −35.62% |
Return on Equity (Normalized) | −33.86% | −44.79% | −39.15% |
Return on Invested Capital (Normalized) | −34.48% | −45.62% | −41.95% |
Return on Assets
CTXR
CRNX
KROS
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Gtkmcqrtyv | Xslk | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Jvdhswps | Nlctzb | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Vgtnwzln | Thrdz | $97.8 Bil | |
MRNA
| Moderna Inc | Qmzgccrml | Zyjv | $41.3 Bil | |
ARGX
| argenx SE ADR | Hxhwlrt | Cmw | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Fsmswjx | Jftd | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Lwbgbmnm | Sfgpyv | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Gkkfkcvk | Hjjxj | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Yhdghpzr | Zkqybs | $12.5 Bil | |
INCY
| Incyte Corp | Qbptlvy | Ryrlp | $11.6 Bil |